(MedPage Today) — The FDA expanded the approval for teplizumab (Tzield), a biologic that delays the progression of preclinical type 1 diabetes to the symptomatic form, to include treatment in kids as young as 1 year, Sanofi announced on Wednesday…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
